$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416099046 Filed on May 05, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q4
Revenue	$2.505M	$4.218M	$5.853M
YoY Change	-82.1%	-57.29%	-12.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.10M	$10.50M	$8.900M
YoY Change	98.59%	81.03%	74.51%
% of Gross Profit
Research & Development	$64.90M	$68.95M	$84.00M
YoY Change	134.07%	143.24%	175.41%
% of Gross Profit
Depreciation & Amortization	$2.100M	$2.000M	$1.700M
YoY Change	40.0%	53.85%	21.43%
% of Gross Profit
Operating Expenses	$64.90M	$68.95M	$84.80M
YoY Change	134.07%	143.24%	138.2%
Operating Profit	-$76.50M	-$75.26M
YoY Change	267.41%	209.55%
Interest Expense	$3.512M	$2.430M	$100.0K
YoY Change	13407.69%	6650.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	-$33.00K	$0.00
YoY Change	-115.28%	-76.76%
Pretax Income	-$79.40M	-$77.30M	-$78.80M
YoY Change	285.44%	216.8%	150.16%
Income Tax
% Of Pretax Income
Net Earnings	-$79.35M	-$77.25M	-$78.81M
YoY Change	284.43%	217.0%	149.81%
Net Earnings / Revenue	-3167.7%	-1831.48%	-1346.42%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.881M	-$5.726M	-$5.837M
COMMON SHARES
Basic Shares Outstanding	270.8M shares	270.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$366.4M	$433.9M	$230.7M
YoY Change	16.35%	32.41%	37.24%
Cash & Equivalents	$89.40M	$132.2M	$93.11M
Short-Term Investments	$277.0M	$301.6M	$137.5M
Other Short-Term Assets	$53.20M	$50.30M	$6.349M
YoY Change	303.03%	337.39%	289.27%
Inventory
Prepaid Expenses
Receivables	$400.0K	$406.0K	$2.320M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$420.0M	$484.6M	$287.3M
YoY Change	26.13%	38.42%	52.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.70M	$36.56M	$32.34M
YoY Change	51.91%	52.53%	63.86%
Goodwill		$53.77M	$53.07M
YoY Change		2.09%	-2.83%
Intangibles		$10.96M	$10.79M
YoY Change		-2.11%	-14.18%
Long-Term Investments
YoY Change
Other Assets	$2.100M	$137.0K	$159.0K
YoY Change	128.76%	-85.08%	-82.68%
Total Long-Term Assets	$105.0M	$107.9M	$98.78M
YoY Change	14.48%	21.6%	12.45%
TOTAL ASSETS
Total Short-Term Assets	$420.0M	$484.6M	$287.3M
Total Long-Term Assets	$105.0M	$107.9M	$98.78M
Total Assets	$525.0M	$592.5M	$386.0M
YoY Change	23.62%	35.02%	39.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.00M	$11.24M	$11.89M
YoY Change	124.81%	15.35%	-7.89%
Accrued Expenses	$31.70M	$27.15M	$26.73M
YoY Change	91.87%	74.13%	37.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$395.0K
YoY Change			-34.49%
Long-Term Debt Due	$100.0K	$300.0K	$400.0K
YoY Change	-80.0%	-50.0%	-33.33%
Total Short-Term Liabilities	$81.90M	$71.05M	$76.49M
YoY Change	202.74%	146.91%	124.22%
LONG-TERM LIABILITIES
Long-Term Debt	$315.6M	$315.3M	$0.00
YoY Change	315500.0%	105000.0%	-100.0%
Other Long-Term Liabilities	$17.40M	$3.248M	$12.70M
YoY Change	23735.62%	3469.23%	675.11%
Total Long-Term Liabilities	$333.0M	$3.248M	$12.70M
YoY Change	456064.38%	3469.23%	675.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.90M	$71.05M	$76.49M
Total Long-Term Liabilities	$333.0M	$3.248M	$12.70M
Total Liabilities	$414.9M	$407.1M	$93.37M
YoY Change	1018.48%	940.18%	101.3%
SHAREHOLDERS EQUITY
Retained Earnings		-$727.3M	-$650.0M
YoY Change		40.55%	31.83%
Common Stock		$2.712M	$2.704M
YoY Change		1.04%	13.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.450M	$2.450M
YoY Change		0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	455.4K shares
Shareholders Equity	$110.1M	$185.4M	$292.7M
YoY Change
Total Liabilities & Shareholders Equity	$525.0M	$592.5M	$386.0M
YoY Change	23.62%	35.02%	39.87%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q4
OPERATING ACTIVITIES
Net Income	-$79.35M	-$77.25M	-$78.81M
YoY Change	284.43%	217.0%	149.81%
Depreciation, Depletion And Amortization	$2.100M	$2.000M	$1.700M
YoY Change	40.0%	53.85%	21.43%
Cash From Operating Activities	-$62.10M	-$69.80M	-$54.80M
YoY Change	404.88%	128.85%	176.77%
INVESTING ACTIVITIES
Capital Expenditures	-$5.500M	-$5.500M	-$4.700M
YoY Change	27.91%	12.24%	95.83%
Acquisitions
YoY Change
Other Investing Activities	$24.50M	-$163.9M	$14.20M
YoY Change	-169.8%	-822.03%	-27.92%
Cash From Investing Activities	$18.90M	-$169.4M	$9.500M
YoY Change	-147.97%	-1051.69%	-45.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	200.0K	278.4M	200.0K
YoY Change	-95.12%	42.4%	-33.33%
NET CHANGE
Cash From Operating Activities	-62.10M	-69.80M	-54.80M
Cash From Investing Activities	18.90M	-169.4M	9.500M
Cash From Financing Activities	200.0K	278.4M	200.0K
Net Change In Cash	-43.00M	39.20M	-45.10M
YoY Change	-9.66%	-78.56%	2047.62%
FREE CASH FLOW
Cash From Operating Activities	-$62.10M	-$69.80M	-$54.80M
Capital Expenditures	-$5.500M	-$5.500M	-$4.700M
Free Cash Flow	-$56.60M	-$64.30M	-$50.10M
YoY Change	607.5%	151.17%	187.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	137548000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	484595000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	287257000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36558000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32342000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10962000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10793000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	53766000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	53065000	USD
CY2016Q1	us-gaap	Assets Assets	592507000	USD
CY2015Q4	us-gaap	Assets Assets	386038000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11237000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11889000	USD
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	252000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	395000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1337000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1409000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	71051000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	76494000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8091000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4171000	USD
CY2015Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9413000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9534000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3248000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3170000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	93369000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	2712000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	2704000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	406000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2320000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132225000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93108000	USD
CY2016Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	301642000	USD
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Trading Symbol TradingSymbol	NVAX
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	270782921	shares
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	29619000	USD
CY2016Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	315271000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	407074000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	920001000	USD
CY2016Q1	us-gaap	Contracts Revenue ContractsRevenue	1946000	USD
CY2015Q1	us-gaap	Contracts Revenue ContractsRevenue	9246000	USD
CY2016Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	2272000	USD
CY2015Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	631000	USD
CY2015Q1	us-gaap	Revenues Revenues	9877000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-75262000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24313000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-77252000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-24370000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	34964000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10528000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5843000	USD
CY2016Q1	us-gaap	Revenues Revenues	4218000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	241223000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	270179000	shares
CY2016Q1	us-gaap	Interest Expense InterestExpense	2430000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	36000	USD
CY2015Q1	us-gaap	Investment Income Net InvestmentIncomeNet	121000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68952000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28347000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	951569000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-727282000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-650030000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7548000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9124000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	185433000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	292669000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	592507000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	386038000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20703000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19317000	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	72000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1598000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27147000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26734000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	137000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	28907000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	34469000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6489000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.1
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-79000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142000	USD
CY2016Q1	us-gaap	Investment Income Net InvestmentIncomeNet	473000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	79480000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	34190000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	317000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1259000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3194000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1576000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3151000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75676000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27521000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1954000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1309000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-146000	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-427000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	-193000	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	-195000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4961000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1932000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1278000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-297000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1926000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	78000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1289000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2491000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1482000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7574000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1644000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	107000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69831000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30490000	USD
CY2016Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5517000	USD
CY2015Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4864000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	19000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	16000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-143000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-164000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193619000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2057000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	195496000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	182715000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215050000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	31000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-98000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	246580000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	82657000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	29450000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32803931	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23250163	shares
CY2015Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	2500000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	301642000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	137548000	USD
CY2016Q1	nvax	Available For Sale Securities Number Of Securities Owned AvailableForSaleSecuritiesNumberOfSecuritiesOwned	69	shares
CY2016Q1	nvax	Available For Sale Securities Number Of Securities Owned Unrealized Losses AvailableForSaleSecuritiesNumberOfSecuritiesOwnedUnrealizedLosses	9	shares
CY2016Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	701000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-146000	USD
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6798000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	278351000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	37000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39117000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32335000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	12000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	301346000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13324000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2362000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2064000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10962000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10793000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12857000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1800000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3800000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	25000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	45000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	45000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	25000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.72
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.99
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.99
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	8.72
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4961000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	53100000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2016Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	100000	USD
CY2015Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	700000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	271226476	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	270771046	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	270426662	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	269971232	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-169440000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	17788000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3180000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3118000	USD
CY2016Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	325000000	USD
CY2015Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 1 Organization</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiary, “Novavax AB,” the “Company”) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using innovative proprietary recombinant nanoparticle vaccine platform technology, the Company produces vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. The Company’s vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant protein antigens critical to disease pathogenesis. The Company’s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (“RSV”), seasonal influenza, pandemic influenza and Ebola virus (“EBOV”).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	7800000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	9100000	USD
CY2016Q1	nvax	Payment For Capped Call Transactions PaymentForCappedCallTransactions	38500000	USD
CY2016Q1	nvax	Debt Cap Price DebtCapPrice	9.73	pure
CY2016Q1	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	315000000	USD
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.56
CY2016Q1	us-gaap	Debt Issuance Costs DebtIssuanceCosts	10000000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4739000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6677000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	9654000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	9794000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	8265000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	42750000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	81879000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	885000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	885000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	756000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	575000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9966000	USD
CY2015Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.45
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0125	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0170	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0119	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5786	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6828	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5358	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5389	pure
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M4D
CY2015Q1	nvax	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.1633	pure
CY2016Q1	us-gaap	Interest Payable Current InterestPayableCurrent	2099000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	237000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2016Q1	nvax	Payment For Capped Call Transactions And Expenses PaymentForCappedCallTransactionsAndExpenses	38521000	USD
CY2015Q1	nvax	Payment For Capped Call Transactions And Expenses PaymentForCappedCallTransactionsAndExpenses	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	664000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	885000	USD
CY2016Q1	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	900000	USD
CY2016Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.56
CY2016Q1	nvax	Reclassified From Other Noncurrent Assets To Restricted Cash ReclassifiedFromOtherNoncurrentAssetsToRestrictedCash	900000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	137569000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	29000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	50000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1535000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayment Terms LongTermDebtMaturitiesRepaymentTerms	7 years
CY2016Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2015Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	USD
CY2016Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	9729000	USD
CY2015Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	USD
CY2016Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2099000	USD
CY2015Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	0	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2336000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Contracts Revenue ContractsRevenue	113000000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	307000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2016Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Reclassifications</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">For the three months ended March 31, 2015, cost </font> of government contracts revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million has been reclassified to research and development expenses<font style="FONT-SIZE: 10pt">, accounts receivable - unbilled of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.9</font> million has been reclassified to accounts receivable and restricted cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.9</font> million has been reclassified from other non-current assets to restricted cash (non-current). These reclassifications have been made to conform to the current year presentation.   </font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	nvax	Adjustments To Additional Paid In Capital Expenses Related To Capped Call Transaction AdjustmentsToAdditionalPaidInCapitalExpensesRelatedToCappedCallTransaction	900000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2016Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	300000	USD

Files In Submission

Name	View Source	Status
0001144204-16-099046-index-headers.html	Edgar Link	pending
0001144204-16-099046-index.html	Edgar Link	pending
0001144204-16-099046.txt	Edgar Link	pending
0001144204-16-099046-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nvax-20160331.xml	Edgar Link	completed
nvax-20160331.xsd	Edgar Link	pending
nvax-20160331_cal.xml	Edgar Link	unprocessable
nvax-20160331_def.xml	Edgar Link	unprocessable
nvax-20160331_lab.xml	Edgar Link	unprocessable
nvax-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v435593_10q.htm	Edgar Link	pending
v435593_ex10-1.htm	Edgar Link	pending
v435593_ex10-2.htm	Edgar Link	pending
v435593_ex10-3.htm	Edgar Link	pending
v435593_ex10-4.htm	Edgar Link	pending
v435593_ex31-1.htm	Edgar Link	pending
v435593_ex31-2.htm	Edgar Link	pending
v435593_ex32-1.htm	Edgar Link	pending
v435593_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2016 Q2 Form 10-Q Financial Statement

#000114420416099046 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2016 Q2 Form 10-Q Financial Statement

#000114420416099046 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax